Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券第一次临时受托管理事务报告（2026年度）
Regulatory Filings Classification · 78% confidence The document is a trustee management report (“受托管理事务报告”) prepared by Guotai Haitong Securities for the convertible bond issuance by 奥锐特药业. It is neither a standalone audit, earnings release, annual/quarterly report, nor call transcript or investor presentation. It is a periodic regulatory report fulfilling trustee duties, which best fits the fallback category of general regulatory disclosures. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-14 Chinese
奥锐特药业股份有限公司关于公司获得药品注册批件的公告
Regulatory Filings Classification · 90% confidence The document is an official corporate announcement by 奥锐特药业股份有限公司 about receiving a drug registration certificate. It contains no financial report data or earnings metrics, nor is it proxy material, dividend notice, or share transaction. It represents a general regulatory disclosure required by the stock exchange/regulator. Therefore, it falls under the fallback “Regulatory Filings” category.
2026-05-11 Chinese
独立董事候选人声明与承诺（苏为科）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board. It details the candidate's qualifications, independence criteria, and compliance with relevant laws and regulations. There is no financial data, no report or announcement of financial results, no mention of meetings or voting results, and no indication of a regulatory filing or legal proceeding. This document is related to board/management information, specifically concerning the nomination and qualifications of a board member. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a standalone declaration by a board candidate.
2026-05-07 Chinese
奥锐特药业股份有限公司关于职工代表大会决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resolution passed at a company's employee representative meeting, specifically about the election of an employee representative director to the board. It includes details about the meeting attendance, voting results, and the biography of the elected director. There is no financial data, no mention of annual or quarterly reports, no audit information, no earnings release, or any other financial or regulatory filing content. The document is a formal announcement related to board/management information, specifically about a change in the company's board composition. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on this announcement, not a report or presentation.
2026-05-07 Chinese
独立董事候选人声明与承诺（钟永成）
Regulatory Filings Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate, detailing qualifications, compliance with regulatory requirements, and independence criteria. It does not contain financial data, audit results, or management discussion. It is not an announcement of a meeting or voting results, nor a report or presentation. It is a regulatory compliance statement related to board membership qualifications. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-05-07 Chinese
独立董事候选人声明与承诺（陈应春）
Regulatory Filings Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is not a financial report, earnings release, or any form of financial or regulatory filing related to financial performance or corporate actions. It does not announce changes in board members but is a candidate's statement. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance-related declaration that does not fit other specific categories.
2026-05-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.